Your session is about to expire
← Back to Search
NBTXR3 + Radiation and Immunotherapy for Metastatic Lung Cancer
Study Summary
This trial is testing a combination of drugs and therapies to treat patients with solid tumors that have spread to the lung or liver. The hope is that the combination will be more effective than any one treatment alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant or breastfeeding.I have been treated for an autoimmune disease in the last 2 years.My targeted lesion has been treated with high-dose radiation before.I have had a stem cell transplant or an organ transplant.I have had one previous treatment with an anti-PD-1 or PD-L1 therapy.I have received a specific high dose radiation treatment.My cancer has spread to my lung, liver, or soft tissue and cannot be cured with surgery or radiation.I can take care of myself and am up and about more than half of my waking hours.I do not have an active, uncontrolled HIV or hepatitis B/C infection.I haven't taken cancer drugs or immunotherapy in the last 2 weeks.I am 18 years old or older.I am willing to use birth control during and up to 5.33 months after the study.I have symptoms from cancer spread to my brain or its coverings.I have no unresolved lung or severe GI issues from past treatments.I've had severe reactions to previous immunotherapy or its ingredients.My cancer lesions can be treated with radiation, as confirmed by my doctor.My cancer can be measured and tracked over time.You must have at least 2 spots that can be measured during the screening.I can have a special injection into up to two cancer spots as decided by my doctor.I am receiving low dose radiation therapy as specified for my treatment.Women who can have children must have a recent negative pregnancy test before receiving the NBTXR3 injection.I have not received any live-virus vaccines in the last 4 weeks.I do not have any severe illnesses that could interfere with the treatment.Your blood counts, kidney function, liver function, and lung function need to be within certain ranges.
- Group 1: Cohort I (NBTXR3, Abscopal, Anti PD-1 / PD-L1
- Group 2: Cohort II (NBTXR3, RadScopal, Anti PD-1 / PD-L1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What common medical conditions is Radiation Therapy prescribed to treat?
"Radiation Therapy has been demonstrated to alleviate the effects of pre-existing anti-angiogenic therapy, malignant neoplasms, and unresectable melanoma."
Is this research currently seeking participants?
"At this juncture, this medical trial is no longer seeking new patients. It was initially uploaded on March 30th 2023 and last modified August 25th 2022. However, there are still 2502 cancer studies searching for volunteers as well as 765 trials related to radiation therapy that need participants."
What previous experiments have utilized Radiation Therapy to further research?
"Currently, there are 765 clinical trials being conducted which explore the efficacy of Radiation Therapy. 86 of these studies have advanced to Phase 3 and can be located at 42755 various research sites around the world – most notably in Pittsburgh, Pennsylvania."
How many participants are being recruited to participate in this experiment?
"Unfortunately, this clinical trial is no longer accepting new applicants. The initial posting was on March 30th 2023 and the last update to the advertisement took place August 25th 2022. Nonetheless, there are numerous other trials actively recruiting cancer patients (2502) or radiation therapy recipients (765)."
Share this study with friends
Copy Link
Messenger